One of the excellent posters on IHUB with a medical background is slcimmuno. He made a post regarding special funding for antibiotics that can go after the superbugs. I read it and made the following reply. After my reply, you can read his post and the linked article he had in it regarding this subject:

My response:
Reading the article you referenced, if there are 6 good candidates in P2 and 1 in P3 then who is getting the current year $550MM for antibiotic research from the below listed funders as noted in your article?

"Principal antibiotic R&D funders (e.g. BARDA, CARB-X, JPIAMR, IMI, the National Institutes of Health (NIH),the Wellcome Trust)"

All IPIX needs is a paltry $40MM to get Brilacidin into P3. Either the antibiotic scare is as serious as the article states it is and these funders should be shoveling money at IPIX or it is a bunch of hot air since the main solutions don't seem to be getting the money to bring the antibiotic solutions into near term commerciality.

slcimmuno post below:
Market Entry Rewards for ABX / BRI mention

Been lots of chatter on this, maybe one day Govts / Others collectively will decide to front some $$$ to prepare for AntibioticApocalypse...

Good to see BRI mentioned as 1 of 7 that likely would be in line for the proposed $1bn... talk about our Shelved Asset suddenly becoming worth Big Bucks overnight

https://www.statnews.com/2018/04/11/innovatio...superbugs/

--